Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.61 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | DRD1 | P21728 | 1/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.56 |
| ▸ | SCN1A | P35498 | 1/20 | 0.56 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.56 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2631380 | 1.00 | POLB (0.61) | POLBESR2MTNR1AADRA2AADRA1A | |
| SCHEMBL31061980 | 1.00 | POLB (0.61) | POLBESR2MTNR1AADRA2AADRA1A | |
| Methyl Alcohol SCHEMBL10973093 | 0.96 | POLB (0.58) | POLBESR2MTNR1AADRA2AADRA1A | |
| SCHEMBL12309752 | 0.85 | POLB (0.62) | POLBESR2MTNR1AADRA2AADRA1A | |
| SCHEMBL7884110 | 0.84 | CA2 (0.58) | POLBESR2MTNR1AADRA2AADRA1A | |
| SCHEMBL12602022 | 0.82 | POLB (0.59) | POLBESR2MTNR1AADRA2AADRA1A | |
| SCHEMBL15203311 | 0.80 | ALDH1A1 (0.55) | POLBESR2MTNR1AADRA2AADRA1A | |
| SCHEMBL18358970 | 0.80 | POLB (0.75) | POLBESR2MTNR1AADRA2AADRA1A | |
| SCHEMBL8367125 | 0.80 | POLB (0.75) | POLBESR2MTNR1AADRA2AADRA1A | |
| SCHEMBL568115 | 0.80 | ADRA2A (0.60) | POLBESR2MTNR1AADRA2AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023244806-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY A | Plexium, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| EP-3356345-B1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-08 | — | — | EP | disclosed |
| US-20230041523-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2023-02-09 | — | — | US | disclosed |
| EP-3562821-B9 | ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE | MINORYX THERAPEUTICS S L (ES) | 2021-05-26 | — | — | EP | disclosed |
| EP-3587420-B1 | TRI-CYCLE COMPOUND AND APPLICATIONS THEREOF | FUJIAN COSUNTER PHARMACEUTICAL CO LTD (CN) | 2021-03-31 | — | — | EP | disclosed |
| CN-112533946-A | Pathogen control composition and use thereof | 旗舰创业创新六公司 | 2021-03-19 | — | — | CN | disclosed |
| EP-3562821-B1 | ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE | MINORYX THERAPEUTICS S L (ES) | 2020-12-02 | — | — | EP | disclosed |
| US-20200339548-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ADORX THERAPEUTICS LTD (GB) | 2020-10-29 | — | — | US | disclosed |
| EP-3725775-A1 | PYRIDINE- AND PYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS | Syntrix Biosystems, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
| US-20200223871-A1 | Arginase Inhibitors and Methods of Use | ASTRAZENECA AB (SE) | 2020-07-16 | — | — | US | disclosed |
| US-20070099875-A1 | Aspartyl protease inhibitors | SCHERING CORPORATION | 2007-05-03 | — | — | US | disclosed |
| US-20070072852-A1 | 2-(Imino-),3,6-(dimethyl-),4-(oxo=),6-(3-(methoxy-)phenyl)-(1,4-phenylene)-perhydropyrimidine; aspartyl protease inhibitors; cardiovascular diseases; cognition activators; neurodegenerative diseases; viricides; HIV; enzyme inhibitors of plasmepins, cathepsin D and protozoal enzymes; hypotensive agents | SCHERING CORPORATION | 2007-03-29 | — | — | US | disclosed |
| US-20070043053-A1 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-22 | — | — | US | disclosed |
| US-20070043095-A1 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | IPSEN PHARMA S.A.S. (FR) | 2007-02-22 | — | — | US | disclosed |
| US-20070021611-A1 | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
| US-20060281729-A1 | Macrocyclic heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION | 2006-12-14 | — | — | US | disclosed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | disclosed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | disclosed |
| WO-2005090291-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2005-09-29 | — | — | WO | disclosed |
| CN-1414963-A | novel heteroaryl derivatives, their preparation and use | LUNDBECK & CO AS H (DK) | 2003-04-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200223871-A1 | Arginase Inhibitors and Methods of Use | ARG1, ARG2, NOS2 | POLB 1908/4885ESR2 3316/4885MTNR1A 1838/4885 |
| US-20200339548-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | TYMP, TYMS, DPYD | POLB 97/4885ESR2 1784/4885MTNR1A 3574/4885 |
| US-20230041523-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS | NLN, GLS, PRNP | POLB 2618/4885ESR2 3357/4885MTNR1A 346/4885 |
| US-20070072852-A1 | 2-(Imino-),3,6-(dimethyl-),4-(oxo=),6-(3-(methoxy-)phenyl)-(1,4-phenylene)-perhydropyrimidine; aspartyl protease inhibitors; cardiovascular diseases; cognition activators; neurodegenerative diseases; viricides; HIV; enzyme inhibitors of plasmepins, cathepsin D and protozoal enzymes; hypotensive agents | CTSD, PRSS1, CTSZ | POLB 1391/4885ESR2 3581/4885MTNR1A 2949/4885 |
| US-20070043053-A1 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | PLK2, CDK2, MAP3K15 | POLB 1629/4885ESR2 1991/4885MTNR1A 1935/4885 |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | SCNN1G, KCNN3, KCNN2 | POLB 4241/4885ESR2 4577/4885MTNR1A 2366/4885 |
| US-20070043095-A1 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | SSTR2, SSTR5, SSTR3 | POLB 4098/4885ESR2 307/4885MTNR1A 52/4885 |
| US-20060281729-A1 | Macrocyclic heterocyclic aspartyl protease inhibitors | CHRM1, CHRM2, CHRM5 | POLB 3264/4885ESR2 1636/4885MTNR1A 628/4885 |
| US-20070021611-A1 | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity | CXCR3, CCR1, CCR5 | POLB 2551/4885ESR2 1336/4885MTNR1A 1049/4885 |
| US-20070099875-A1 | Aspartyl protease inhibitors | PRSS1, PRSS3, TMPRSS11D | POLB 2426/4885ESR2 3342/4885MTNR1A 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.